Sector News

Endo looks to acquire Auxilium in $2.2 billion deal

September 17, 2014
Life sciences
Endo International is looking to acquire Auxilium Pharmaceuticals in a deal worth $2.2 billion.
 
Its offer of $28.10 per share in cash and stock represents a premium of 31% to Auxilium’s closing price yesterday (September 16), though the latter’s shares shot up 37% to over $29.50 in after-hours trading.
 
The chief attraction of Endo is Xiaflex (collagenase clostridium histolyticum) which is approved in the USA for Dupuytren’s contracture, which affects the connective tissue beneath the skin in the palm of the hand, and Peyronie’s disease, which causes a bothersome curvature of the penis during sex. It has a total of 12 Food and Drug Administration-approved products in urology, orthopaedic and other areas, including Stendra (avanafil), an oral erectile dysfunction drug, which are “natural complements to the men’s health and pain products in Endo’s pharmaceuticals portfolio”, the latter firm claims.
 
Rajiv De Silva, Endo chief executive, said the proposal would provide Auxilium shareholders “a substantial premium and immediate cash value for their investment…as well as the opportunity to participate in the upside potential of a leading global specialty healthcare company”. He added that Endo “stands ready to engage immediately with Auxilium, complete our confirmatory diligence, negotiate a definitive agreement and complete this exciting transaction”.
 
Auxilium is saying nothing for the moment about the Endo bid but just a week ago announced it was reducing its headcount by 30% in a bid to reduce operating expenses by more than $75 million. It is also in the process of acquiring Canadian biotech QLT.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend